Introduction
Short-term safety and efficacy of transcatheter aortic valve implantation (TAVI) in symptomatic severe aortic stenosis patients at high and extreme risk for surgery has been established in several prospective clinical trials. [1] [2] [3] [4] More recently, TAVI has been shown to be non-inferior to surgical valve replacement in symptomatic patients, deemed intermediate risk for surgical intervention, 5, 6 and data from one randomized, clinical trial have demonstrated similar safety and efficacy to surgery in low-risk patients with symptomatic severe aortic stenosis. 7 As adoption of TAVI expands into younger and lower risk patients, longer term clinical outcomes and bioprosthetic valve durability are of increasing importance. Although clinical outcomes through 3 to 5 years from multiple randomized clinical trials [8] [9] [10] provide evidence for the safety of TAVI in higher risk patients, questions regarding bioprosthetic valve durability remain a concern. [11] [12] [13] The CoreValve ADVANCE study is a prospective, global multicentre observational clinical study that evaluated the self-expanding CoreValve bioprosthesis for TAVI in a real-world population. Unlike other large registries that may have under-reported adverse events, the ADVANCE study was fully monitored, and all events were independently adjudicated. Complete 5-year clinical and echocardiographic data are now available. Additional post hoc analyses were conducted to evaluate bioprosthetic valve durability through 5 years and factors impacting mortality.
Methods

Patients and study design
Patient selection and design of the ADVANCE study have been previously described. 14 Briefly, ADVANCE is a global, prospective, non-randomized, multicentre clinical study that enrolled real-world patients with symptomatic, severe aortic valve stenosis suitable for TAVI. Participants were enrolled at 44 centres from 12 countries; all centres were required to have TAVI experience of at least 40 cases. Each centre was also required to have a Heart Team comprised of at least one TAVI-experienced interventional cardiologist and one cardiothoracic surgeon to evaluate patient suitability for TAVI. The ADVANCE study complied with the Declaration of Helsinki, with approval of the research protocol from all locally appointed ethics committees, and informed consent was obtained from all patients or their legally authorized representative. Description of the CoreValve bioprosthesis and corresponding implant details have been presented previously. 15, 16 CoreValve sizes of 26 and 29 mm were available during the ADVANCE study to treat aortic valve annulus sizes from 20 mm to 27 mm. Each centre's Heart Team determined the access route (iliofemoral, direct aortic, or subclavian) and type of anaesthesia (general or conscious sedation) for each patient. Follow-up visits were scheduled at 30 days and then annually up to 5 years. The primary endpoint of the ADVANCE study was major adverse cardiac and cerebrovascular events at 30 days post-procedure, defined as a composite of all-cause mortality, myocardial infarction, stroke, or reintervention. Additional clinical endpoints included cardiovascular mortality, vascular complications, major and minor stroke, and new pacemaker implantation. The study was fully monitored, and adverse events were adjudicated by an independent clinical events committee comprised of interventional cardiologists and cardiac surgeons using definitions from Valve Academic Research Consortium (VARC-1). 17 The committee reviewed patient source data as well as assessments from an independent neurologist to adjudicate all events.
Echocardiographic analysis
Echocardiographic data are reported by each investigative centre. Mean gradient; effective orifice area (EOA); and total and paravalvular aortic regurgitation (AR) data at baseline, discharge, 1 month, and annually to 5 years were analysed.
Prosthetic valve durability analysis
Prosthetic valve durability was assessed post hoc using echocardiographic data and VARC-2 definitions. 18 This analysis used the last available echo post 30 days after implantation or the last echo before a reintervention greater than 30 days post-procedure; only patients who had an echo in at least one of these categories were included in the analysis. Surgical criteria for aortic valve stenosis was defined as a greater than 50% increase of mean gradient from 1 month to 5 years. 19 
Statistical analysis
Continuous variables are reported as the mean ± standard deviation. Categorical variables are reported as the number and percentage. Clinical outcomes were calculated using Kaplan-Meier survival analysis, and freedom from mortality curves were also generated using KaplanMeier methods. The log-rank test was used to test for differences across and between groups. For subjects without an event, the date of censoring was the latest date of all follow-up visits (including study exit) and events (including death). Predictors of mortality at 5 years were evaluated using univariable and stepwise multivariable Cox regression models with an entry P-value of 0.1 and a stay P-value of 0.05. Hazard ratios with twosided 95% confidence interval (CIs) were calculated. All tests were two sided. All analyses were performed using SAS software (Cary, NC, USA), version 9.2 or above.
Results
Patient and procedural characteristics
Baseline characteristics and procedural data for patients enrolled in ADVANCE have been described previously. 14 In brief, from March 2010 to July 2011, 1015 patients were enrolled and TAVI procedures were attempted in 996 patients; 49.3% of patients were male, mean age was 81 years, 80.0% were in NYHA Class III or IV, the mean STS score was 6.4 ± 4.4%, and the mean logistic EuroSCORE was 19.3 ± 12.3%. Additional baseline characteristics can be found in Supplementary material online, Table S1 . For TAVI procedures, iliofemoral access was used in 88.4% of patients, subclavian access in 9.5% and 2.1% had direct aortic access. 14 Figure S1 ).
Clinical outcomes and predictors of mortality
Clinical outcomes at 1 and 5 years are shown in Table 1 . At 5 years, the rate of all-cause mortality was 50.7%, all-cause mortality or major stroke was 51.8%, and cardiovascular mortality was 33.5% ( Figure 1A ). The rate of stroke at 5 years was 10.2% with approximately half ajudicated as major stroke (5.4%) ( Figure 1B ). The rate of new pacemaker implantation within 30 days post-TAVI was 33.7% at 5 years but was not associated with an increase in mortality ( Figure 2A ). When rates of freedom from all-cause mortality were stratified by EuroSCORE the highest baseline EuroSCORE was associated with the worst survival through 5 years ( Figure 2B ). The impact of discharge AR is shown in Figure 2C . Moderate or severe AR was associated with the lowest survival (45.2% at 5 years). There also appears to be an impact of mild AR on mortality demonstrated only after 2 years with a rate of 50.7% at 5 years. NYHA classification for 320 patients who were assessed at all time points of baseline, 1 month, and annually to 5 years indicated a gradual increase in Class III symptoms during Years 3 through 5, but the majority of patients remained Class I or II (80.9%) (see Supplementary material online, Figure S2 ).
Multivariable predictors of mortality through 5 years are shown in Figure 3 ; complete univariable and multivariable predictors are found in Supplementary material online, Table S2 . Multivariable predictors of mortality were age, presence of peripheral vascular disease, chronic obstructive lung disease, elevated serum creatinine, baseline left ventricular ejection fraction < _50%, major bleeding and Stage 3 acute kidney injury. Higher baseline mean aortic valve gradient was associated with lower mortality.
Echocardiographic measures
Echo compliance decreased over time with a follow-up rate of 67% at Years 3 and 4 and 56% at 5 years. There were 125 patients with AR measurements at baseline and all follow-up time points (discharge, 1 month, and annually to 5 years). At 5 years, 40.8% of these paired patients had no AR, compared with 21.6% at discharge. Degree of moderate AR went from 12.8% at discharge to 8.0% at 5 years, and no patients had severe AR from discharge to 5 years, inclusively ( Figure  4A) . Similarly, Figure 4B shows AR for all patients, including a category for patients who were deceased or had a missed visit. Mean aortic valve effective orifice area and mean gradient from baseline to 5 years are shown in Figure 5 . In patients with data at baseline and 5 years mean gradient dropped from 45.3 ± 15.9 at baseline to 9.8 ± 4.4 mmHg at discharge and 8.8 ± 4.4 mm Hg at 5 years (n = 198). Mean gradient measurements for all available patients vs. patients with echocardiographic follow-up at all time points are shown in Supplementary material online, Table S3 . Mean EOA for paired patients was 0.8± 0.5 at baseline and 1.7 ± 0.4 cm 2 at 5 years (n = 123).
Prosthetic valve durability
The incidence of structural valve deterioration was site reported as 0.9% at 5 years. Additional post hoc analysis on durability of the CoreValve bioprosthesis was analysed in 860 patients ( Table 2) . Mean follow-up time was 36.0 ± 21.1 months, and 267 patients had follow-up through 5 years. There was a >50% increase in baseline mean gradient in 9.3% of patients and the rate of valve dysfunction per VARC-2 criteria was 2.6% (n = 22) at 5 years of follow-up. Two of the 22 patients meeting criteria for aortic valve stenosis also had a reintervention, 10 patients had a high mean gradient or peak velocity, 11 patients had moderate or severe AR, and 1 patient had a high mean gradient and peak velocity plus moderate AR (Figure 6 ). Ten (1.2%) patients had reinterventions after 30 days postprocedure, where 4 procedures were surgical reinterventions and 6 were percutaneous. For these 10 reinterventions, 2 were caused by prosthetic degeneration and subsequent aortic stenosis. Additional details on the patients and their reintervention procedures are found in Supplementary material online, Table S4 .
Of the 996 patients, 1.8% (18 patients) were diagnosed with endocarditis, where 2 patients had 2 occurrences each of endocarditis. Thirty-five per cent of cases were related to the prosthetic valve and 4 cases occurred within 6 months of the procedure. Three patients died due to endocarditis.
Discussion
The CoreValve ADVANCE clinical study provides longer term data on a large, real-world international population of TAVI patients. 14, 20, 21 The 5-year results from ADVANCE continue to demonstrate the strong haemodynamic performance of the CoreValve bioprosthesis, as well as low rates of stroke, AR, and a 5-year mortality rate within the expected range for this elderly TAVI population.
As the first TAVI procedure was performed just 15 years ago, to date, there are only a few multicentre clinical studies with reported results from 5 years of follow-up. 9, 13, 22 All-cause mortality for patients in the CoreValve ADVANCE study was 50.7% (95% CI: 46.7%, 54.5%) at 5 years, similar to results described by Barbanti [55% (95% CI: 49-60%)] 13 and Duncan (54.5%). 22 PARTNER 1, a randomized controlled trial of TAVI vs. surgical implantation, reported all-cause mortality of 67.8% at 5 years, 9 higher than ADVANCE, potentially due to differences in study design and baseline risk of enrolled patients (STS score of 10.7 ± 3.5% for PARTNER 1 vs. 6.4 ± 4.4% for ADVANCE). Likewise, cardiovascular mortality was 33.5% at 5 years in ADVANCE and 53.1% for PARTNER 1. 9 Barbanti et al. 13 reported Final five-year results for treatment of severe aortic stenosis with a self-expanding transcatheter bioprosthesis There are limited data on rate of stroke at 5 years post-TAVI. The rate of stroke at 5 years in ADVANCE was 10.2%, similar to the rate of 10.4% in PARTNER 1. 9 The Italian registry reported a 5-year stroke rate of 7.5%. 13 A number of clinical studies have described an early incidence of strokes post-TAVI, followed by lower rates of stroke over time. 13, 23 Similarly, in ADVANCE, the stroke rate at 30 days post-TAVI was 3.0%, and increased at a much slower rate after that to 5 years.
The observed continued improvement in AR over time for paired patients followed through 5 years are confirming of the findings from the US CoreValve Pivotal Trial 8 and may be related to continued valve frame expansion or tissue ingrowth over time. An evaluation of surgical bioprosthetic valve explants suggests that an increase in mean gradient of >50% over discharge may correlate with valve thrombosis. 19 A recent presentation further showed an association between subclinical leaflet thrombosis and a higher rate of transient ischemic attacks. 24 There was no measure of valve thrombosis in ADVANCE; however, 9.3% of patients had a 50% or more increase in mean gradient. Additional clinical studies are ongoing to further assess the relationship between leaflet immobility, subclinical thrombosis, and clinical outcomes. In ADVANCE, we identify a low rate of reinterventions after 30 days that is consistent with reports from other studies. There were 2 cases (0.6%) with aortic valve reintervensions with the CoreValve bioprosthesis in the Italian registry; both were valve-in-valve TAVI procedures occurring between 4 and 5 years. 13 Moreover, there were 3 patients with prosthetic dysfunction who did not undergo reintervention: 1 case of endocarditis, 1 case of asymptomatic valve degeneration with severe AR and 1 case of worsening (moderate-tosevere) paravalvular regurgitation. Three-year follow-up of the CoreValve High-Risk US pivotal trial reported a reintervention rate of 2.5% in patients receiving TAVI but noted that the majority of these events occurred before 30 days. 8 Although 22 patients in ADVANCE met VARC-2 criteria for aortic stenosis, only 2 had reinterventions. The low rate of reintervention and aortic valve stenosis assessed after 30 days provides reassuring data regarding the durability of the self-expanding CoreValve through 5 years. The analysis set included subjects with at least 1 echo post 30 day or reintervention >30 days; 267 patients had follow-up at 5 years. Predictors of mortality through 5 years were consistent with those identified at 1 year.
14 Peripheral vascular disease, elevated serum creatinine, low ejection fraction, and acute kidney injury remained as predictors and as expected, greater age is associated with a higher risk for mortality through 5 years. When freedom from mortality was stratified by degree of AR, we noted lower rates of survival for patients with moderate/severe and mild AR (detectable after 2 years) at discharge, suggesting that AR may contribute to higher mortality over time. The FRANCE-2 Registry, which enrolled over 3000 patients, found that moderate-to-severe post-procedural AR was the strongest independent predictor of 1-year mortality. 25 Patients who received a new pacemaker within 30 days post-procedure had similar 5-year survival to patients with an existing pacemaker or no pacemaker (log-rank P = 0.48). This is consistent with previous CoreValve clinical studies that did not find any increase in mortality between patients with and without a new pacemaker. 7, 26 There are several limitations in our analysis. Echo visit compliance at 5 years was only 56% and assessment of haemodynamic valve function overtime may underestimate the rate of valve dysfunction at 5 years. It is possible that patients who died during the study duration without a recent echo may have had undiagnosed valve deterioration, but the available echo data argue against a premature valve deterioration. It is likely that some patients with AR died earlier in the study, which affects the proportion of patients with mild or greater AR at 5 years. Nevertheless, the paired echo data indicates that AR is improving over time. In addition, echo measurements were site reported, as there was no echo core lab adjudication for this study.
The 5-year results from the ADVANCE clinical study demonstrated consistent low mean aortic valve gradients associated with the self-expanding CoreValve and provide insights into longer term clinical outcomes for 'real-world' TAVI patients. Analysis of bioprosthetic valve durability through 5 years further demonstrated low rates of reinterventions and haemodynamic valve dysfunction. As the use of TAVI moves into lower risk, younger patients continued follow-up will be essential to reassure physicians and patients of the long-term safety of TAVI.
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